You just read:

Neuraltus Announces Completion of Enrollment in Confirmatory Phase 2 Study of NP001 in ALS Patients with Systemic Inflammation

News provided by

Neuraltus Pharmaceuticals, Inc.

Jul 12, 2017, 08:00 ET